OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
An agreement with Sanofi gives Catalent access to commercial spray drying facility in Haverhill, UK.
Catalent announced an expansion of the company’s global spray drying capacity through an agreement with Sanofi Active Ingredient Solutions, which gives Catalent access to spray drying manufacturing equipment at Sanofi’s Haverhill, United Kingdom facility.
This agreement, announced via press statement on July 9, 2019, gives Catalent access to the Niro (GEA) PSD2 and PSD4 spray driers at the facility for customer projects. The facility includes clean area facilities for solvent and aqueous processing of potent or non-potent drug formulations, a secondary vacuum dryer, and integrated quality control and analytical capabilities.
Catalent reports that the company can now offer spray drying solutions from early-phase development through commercial finished dose form manufacturing in Europe.
“This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site with expertise in commercial-scale spray dried dispersions, which are frequently used today to overcome the solubility challenges with many new medicines,” said Jonathan Arnold, president of Catalent’s oral drug delivery business unit.
“Sanofi Haverhill is our center of excellence for spray drying technology. The site has over a decade of experience in spray drying operations for commercial manufacture. We welcome the relationship with Catalent and are delighted that Catalent is investing in the innovation and resources at our UK facility,” said Philippe Clavel, Head of Sanofi Active Ingredient Solutions.
Earlier this year, Catalent announced a $40-million investment in its Winchester, KY facility, which includes commercial-scale spray drying with high-potent handling capabilities and other increases to the site’s capacity.